Document is current
Any future updates will be listed below
-
Authors
Talks, James
de Salvo, Gabriella https://orcid.org/0000-0002-1185-6942
Patel, Praveen J. https://orcid.org/0000-0001-8682-4067
de Silva, Samantha R.
Gale, Richard P. https://orcid.org/0009-0006-0213-6253
McKibbin, Martin https://orcid.org/0000-0003-4388-243X
Varma, Deepali
Pearce, Ian
Peto, Tunde https://orcid.org/0000-0001-6265-0381
Reynolds, Rhianon
Bailey, Clare https://orcid.org/0000-0003-2141-4512
Downey, Louise
Kiire, Christine A. https://orcid.org/0009-0001-4424-9129
Sivaprasad, Sobha
Downey, Amanda K.
James, Natalee
Chi, Gloria C.
Dodds, Melanie https://orcid.org/0009-0007-8748-5299
Dayal, Parul
-
Funding
Funding for this research was provided by:
F Hoffmann-La Roche - funded study and medical writing support
- License Information
-
More Information
Article History
Received: 7 April 2025
Revised: 6 November 2025
Accepted: 19 December 2025
First Online: 10 March 2026
Competing interests
: JT: Advisory Board: Bayer, Roche; Consultancy: Bayer, Roche; Speaker: Alimera, Bayer, Heidelberg Engineering, Roche; Travel Support: Bayer, Heidelberg Engineering, Roche; Research: Bayer, Boehringer Ingelheim, Janssen, Roche. GdS: Advisory Board: AbbVie, Apellis, Astellas, Bayer, Novartis, Roche, Teva; Consultancy: Boehringer Ingelheim, Roche; Speaker/Travel Support: AbbVie, Bayer, Heidelberg Engineering, Novartis, Roche. Section Editor: Eye Journal. PJP: Advisory Board: Bayer, Boehringer Ingelheim, Genentech, Inc., Novartis, Roche; Honoraria/Educational Grant: Bayer, Roche; Research Funding: Bayer. SRdS: Consultancy: AbbVie, Bayer, Roche; Travel Support: Bayer, Roche. RPG: AbbVie, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Novartis, Ocular Therapeutix, Roche, Santan. MM: Advisory Board: Apellis, Roche; Consultancy: Roche; Speaker: Bayer; Travel Support/Educational Grant: Bayer, Roche. DV: Advisory Board/ Honoraria: AbbVie, Astellas, Bayer, Outlook Therapeutics, Roche, Teva; Educational Travel Grants: AbbVie, Alimera, Bayer, Roche; Clinical Trial PI: AbbVie, Bayer, EyeBio, Novartis, Roche. IP: Advisory Board/Consulting/Honoraria/Travel Expenses: Roche. TP: Advisory Board: Alimera, Allergan, Apellis, Bayer, Novartis, Optos, Roche, ZEISS; Consultancy: Boehringer Ingelheim, Roche; Investigator-Initiated Grant: Boehringer Ingelheim, Novartis; Speaker: Alimera, Allergan, Bayer, Heidelberg Engineering, Novartis, Optos, ZEISS. RR: Advisory Board/Honoraria: Roche; Grant Support: Macular Society. CB: Advisory Board/Honoraria/Travel Support: Alimera, Apellis, Bayer, Boehringer Ingelheim, Janssen, Novartis, Roche. LD: Advisory Board/Honoraria: Alimera, Allergan, Bayer, Biogen, Novartis, Roche; Travel Grants: Allergan, Bayer, Novartis. CK: Advisory Board/Consulting/Honoraria/Travel Expenses: Alimera, Bayer, Boehringer Ingelheim, Roche. SS: Funding/Fees: AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, EyeBio, EyePoint, Janssen, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Kriya Therapeutics, Roche, Sanofi, Stealth. AKD: Employee: F. Hoffmann-La Roche Ltd., NJ: Employee: Roche Products Ltd., GC: Employee: Genentech, Inc., MD: Employee: Medisoft Ltd., PD: Employee: Genentech, Inc.
